CASE STUDY — REBRAND

Getting a Global Genomics Company Ready to Walk Into JPM

How strategic messaging preparation before a high-stakes investor event changed how the market saw MedGenome.

A global genomics company preparing for JPM 2024 had strong scientific credibility but a fragmented and outdated story. Different functions described the platform differently. Sales was selling assays, leadership eas pushing for a solution focus. Investors heard competing versions and inconsistent future vision for medgenome. We built one version that made sense to all.

The Challenge

MedGenome had built real scientific depth. But approaching JPM 2024, the story coming from different parts of the organization was inconsistent. Researchers talked about the omics. Commercial teams described assays. The brand hadn't caught up to what the company had become: a solution provider.The risk wasn't the science. It was arriving at a high-visibility investor event with three versions of the same story, looking like a liability rather than a worthy global contender against larger companies.

Solution

Shift the brand narrative from product provider to full-service solutions partner.

Working across functions, I built a single narrative architecture for the platform: what it does, why it matters for biopharma partners, and how to describe the integrated offering without flattening the science.The positioning was tested against investor language, partner-facing language, and the internal teams who would have to use it. The website and go-to-market materials followed from that foundation.

Outcome

The refreshed positioning debuted at JPM 2024 and was received well by industry and investor audiences. Strategic partnerships followed. The messaging infrastructure supported U.S. market expansion and laid the foundation for the 2025 rebrand to Signios Bio.

Why it Matters

This work helped transform MedGenome from a transactional testing provider into a trusted innovation partner. This shift elevated their market perception and enabled the business growth that led to their evolution as Signios Bio. It's a prime example of how clear, strategic messaging, when paired with a well-executed digital presence, can unlock next-level traction in complex B2B markets.

Here's how we help our clients maintain credibility before milestones.

Narrative Risk Audit

See where your story fragments before partners do.

Learn More

Standards Concept. Word on Folder Register of Card Index. Selective Focus.

Narrative Alignment Sprint

One science. One story. Zero conflicting versions.

Learn More

Policies Concept. Word on Folder Register of Card Index. Selective Focus.

Truth Architecture Build

Infrastructure that makes consistency inevitable, not aspirational.

Learn More